Literature DB >> 3890731

Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans.

F Bistoni, A Vecchiarelli, R Mazzolla, P Puccetti, P Marconi, E Garaci.   

Abstract

Mice receiving a single intraperitoneal injection of amphotericin B showed increased resistance to subsequent challenge with either Candida albicans or Staphylococcus aureus. This enhancement of resistance was obvious in terms of both survival criteria and clearance of the intravenously injected organism from different organs. The protective effect of amphotericin B was conditioned by dose, time of drug administration, and size of yeast or bacterial inoculum and was reversed by cyclophosphamide. Effector cells from mice treated with amphotericin B displayed enhanced fungicidal activity in vitro as measured in a short-term 51Cr release assay. Macrophages from intact animals exposed in vitro to amphotericin B also acquired strong candidacidal reactivity.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3890731      PMCID： PMC180109          DOI： 10.1128/AAC.27.4.625

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Spectrum of in vivo and in vitro cell-mediated immune responses in coccidioidomycosis.

Authors:  R A Cox; J R Vivas
Journal:  Cell Immunol       Date:  1977-06-01       Impact factor: 4.868

2.  Augmentation of murine immune responses by amphotericin B.

Authors:  T J Blanke; J R Little; S F Shirley; R G Lynch
Journal:  Cell Immunol       Date:  1977-09       Impact factor: 4.868

3.  Changes in murine resistance to Listeria monocytogenes infection induced by amphotericin B.

Authors:  M Z Thomas; G Medoff; G S Kobayashi
Journal:  J Infect Dis       Date:  1973-04       Impact factor: 5.226

4.  Immunology of the mycoses. I. Depressed lymphocyte transformation in chronic histoplasmosis.

Authors:  W M Newberry; J W Chandler; T D Chin; C H Kirkpatrick
Journal:  J Immunol       Date:  1968-02       Impact factor: 5.422

5.  Mucocutaneous candidiasis, anergy and a plasma inhibitor of cellular immunity: reversal after amphotericin B therapy.

Authors:  P Y Paterson; R Semo; G Blumenschein; J Swelstad
Journal:  Clin Exp Immunol       Date:  1971-11       Impact factor: 4.330

6.  Effects of amphotericin B on macrophages and their precursor cells.

Authors:  S H Lin; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

7.  [Use of potassium chloride hypertonic saline solution (3M KC1) for extraction of soluble antigens from Candida albicans].

Authors:  P Marconi; F Bistoni; L Boncio; A Bersiani; P Bravi; M Pitzurra
Journal:  Ann Sclavo       Date:  1976 Jan-Feb

8.  Amphotericin B pharmacokinetics in humans.

Authors:  A J Atkinson; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

9.  Phagocytic killing of Candida albicans by different murine effector cells.

Authors:  M Baccarini; E Blasi; P Puccetti; F Bistoni
Journal:  Sabouraudia       Date:  1983-12

10.  Response of transplanted AKR leukemia to combination therapy with amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea: dose and schedule dependency.

Authors:  G Medoff; F Valeriote; J Ryan; S Tolen
Journal:  J Natl Cancer Inst       Date:  1977-04       Impact factor: 13.506
View more
  16 in total

1.  Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections.

Authors:  S Mizutani; M Endo; T Ino-Ue; M Kurasawa; Y Uno; H Saito; I Kato; K Takesako
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Interleukin-12 modulates the protective immune response in SCID mice infected with Histoplasma capsulatum.

Authors:  P Zhou; M C Sieve; R P Tewari; R A Seder
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

3.  Evidence for macrophage-mediated protection against lethal Candida albicans infection.

Authors:  F Bistoni; A Vecchiarelli; E Cenci; P Puccetti; P Marconi; A Cassone
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

4.  Activity of amphotericin B and intraconazole against intraphagocytic Candida albicans.

Authors:  E Ponce; J C Pechère
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

5.  Virulence attenuation of Candida albicans genetic variants isolated from a patient with a recurrent bloodstream infection.

Authors:  Paula Sampaio; Marlene Santos; Alexandra Correia; Fábio E Amaral; Julio Chavéz-Galarza; Sofia Costa-de-Oliveira; António G Castro; Jorge Pedrosa; Célia Pais
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

6.  Combined effect of fluconazole and thymosin alpha 1 on systemic candidiasis in mice immunosuppressed by morphine treatments.

Authors:  P di Francesco; R Gaziano; I A Casalinuovo; L Belogi; A T Palamara; C Favalli; E Garaci
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

7.  Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis.

Authors:  J R Perfect; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

8.  Novel aspect of amphotericin B action: accumulation in human monocytes potentiates killing of phagocytosed Candida albicans.

Authors:  E Martin; A Stüben; A Görz; U Weller; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

9.  Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.

Authors:  Henry W Murray; Elaine B Brooks; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  Contribution of granulocytes and monocytes to resistance against experimental disseminated Candida albicans infection.

Authors:  J W van 't Wout; I Linde; P C Leijh; R van Furth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.